SIGA Technologies - TPOXX trials launched in treating monkeypox
SIGA Technologies has shared an update on the progress of three clinical trials assessing TPOXX for treating monkeypox. Recently, three randomized, placebo-controlled trials were launched in the US, UK and Democratic Republic of Congo (DRC) to assess the safety and efficacy of TPOXX in treating patients with monkeypox. The US and UK trials are both aiming to enroll more than 500 participants, while the DRC is targeting over 450. Positive trial results should boost TPOXX order momentum in the US and other nations, as management plans to file with US regulators for a regulatory review of a TPOXX expanded indication for treating monkeypox. We maintain our valuation of $19.80 per share.SIGA Technologies is a commercial-stage pharmaceutical company focused on the health security market. Health security comprises countermeasures for biological, chemical, radiological and nuclear attacks, vaccines and therapies for emerging infectious diseases, and health preparedness. The company's primary product is an oral formulation of TPOXX?, an antiviral drug for the treatment of human smallpox disease caused by variola virus. The United States Food and Drug Administration has approved oral TPOXX? for the treatment of smallpox.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.